RE:RE:RE:RE:RE:60% of the road = 270-daysLaserStock29 wrote: Camphikefish wrote: Looks like we need to come in at 25-30 % at a minimum with our 12 month CR data. Thoughts on our chances/probability?
3/10 was known wayback 1993 photofrin 60% w damages to organ 2022 we better minimum be over 60%
I believe since NMIBC, via instilations, is so in-exact. We might be doing pretty well with %s in the 40s or 50s. Maybe we get as high as the 60s after AA and the much higher numbers of patients. Solid tumor indications is I think where TLT could see very high percentages.
Of course the best thing about TLTs ACT is how safe and repeatable it is. Turning NRs to PRs to CRs.
Sure, I wish some of this was priced in to the stock by now.....